ArticleScientific reports2026
Association of ACAG with short-term mortality in liver failure patients: a retrospective analysis based on the MIMIC-IV database.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional scoring systems are challenging for early diagnosis and intervention in liver failure. While albumin-corrected anion gap (ACAG) predicts adverse outcomes in various conditions, its effectiveness in liver failure remains unclear. This study analyzed hepatic failure patients from MIMIC-IV, stratified into Q1-Q4 by ACAG quartiles. Kaplan-Meier survival curves examined mortality differences. The connection of ACAG with mortality was examined using Cox regression and restricted cubic spline (RCS) analyses. Additionally, we compared the predictive performance of ACAG, MELD, and their combination for mortality using receiver operating characteristic (ROC) curve analysis, calculated the area under the curve (AUC), and compared the AUC values using the DeLong test. Finally, subgroup analyses were conducted to evaluate the relationship between ACAG and prognosis in different types of liver failure. Current study involving 2,016 patients with liver failure revealed 30- and 90-day mortality rates of 27.23% and 30.01%, respectively. Kaplan-Meier survival curves demonstrated mortality increased with ACAG levels. Multivariate Cox regression confirmed ACAG’s positive association with mortality [HR 1.032 (30-day), 1.031 (90-day); both P < 0.001], and the RCS showed a linear relationship. The AUCs for 30-day mortality were 0.641 (ACAG), 0.634 (MELD), and 0.668 (combined); the corresponding values for 90-day mortality were 0.630, 0.621, and 0.654. The AUC of the combined model was significantly higher than that of ACAG alone (P = 0.0009 and 0.0016) and MELD alone (P = 0.0004 and 0.0002) for 30- and 90-day mortality, respectively. Although ACAG yielded a marginally higher AUC than MELD, DeLong’s test indicated no significant difference (P = 0.7035 and 0.5387 for 30-and 90-day mortality, respectively). Subgroup analyses observed interactions in the age subgroups and CRRT subgroups; ACAG was consistently elevated in non-survivors across all liver-failure subtypes. Our study demonstrates that the ACAG index is significantly associated with mortality in patients with hepatic failure; its integration with the MELD score further enhances predictive accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.